90K immunostimulatory glycoprotein in children with juvenile idiopathic arthritis

Area of Science:

• Biochemistry
• Immunology
• Pediatric Rheumatology

Background:

• Juvenile idiopathic arthritis (JIA) is a chronic autoimmune disease affecting children.
• Biomarkers are crucial for understanding disease activity and treatment response in JIA.
• 90K glycoprotein is a potential biomarker whose role in JIA requires further investigation.

Purpose of the Study:

• To determine if circulating 90K glycoprotein levels are elevated in children with JIA.
• To compare 90K levels across different JIA disease stages and healthy controls.
• To assess changes in 90K levels following treatment with etanercept, an anti-tumor necrosis factor (TNF) drug.

Main Methods:

• Assessed 90K glycoprotein, C-reactive protein, ESR, and JADAS in 71 children (23 new JIA, 23 active JIA, 25 controls).
• Evaluated patients eligible for anti-TNF therapy with a 6- and 12-month follow-up after etanercept treatment.
• Measured other relevant markers including TNF, antinuclear antibodies, and rheumatoid factor.

Main Results:

• Significantly higher 90K glycoprotein levels were observed in children with JIA at onset compared to established JIA and controls (p < .001).
• Following 12 months of etanercept treatment, 90K levels significantly decreased at 6 months (p = .001) and further declined at 12 months (p < .001).
• Baseline 90K levels were 157.7 μg/ml in new JIA, 90.0 μg/ml in treated JIA, and 58.0 μg/ml in controls.

Conclusions:

• Circulating 90K glycoprotein levels are elevated in children with JIA, indicating a potential pathogenetic role.
• Etanercept therapy over 12 months effectively reduces 90K glycoprotein levels in JIA patients.
• 90K glycoprotein shows promise as a biomarker for disease activity and treatment response in JIA.